Literature DB >> 16849779

Developing a blood conservation program in cardiac surgery.

Abe DeAnda1, Kathy M Baker, Susan D Roseff, Jeffrey A Green, Harry McCarthy, Tyrone Aron, Bruce D Spiess.   

Abstract

The beneficial effects of blood transfusions have been described and widely accepted. Multiple factors, including shortages, costs, infectious risks, immunologic risks, and the risk/benefit ratio to the patient, have made the medical community reassess the guidelines for transfusion. Cardiac surgery presents a unique subset of patients, because intervention at multiple stages in the care of these patients is possible to decrease the need for transfusion. An algorithm for a cardiac surgery program was developed and a reassessment performed. Once it was seen that no detrimental effect on patient care occurred, the program was expanded, was enhanced, and subsequently has been offered to the rest of the health care system. This program has resulted in a decrease in cost while maintaining patient outcomes. The success of the program is believed to be a result of the multidisciplinary approach taken, with a commitment from all members of the blood reduction team being the key component of this success.

Entities:  

Mesh:

Year:  2006        PMID: 16849779     DOI: 10.1177/1062860606289784

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  3 in total

1.  The Impact of a Blood Conservation Program in Complex Aortic Surgery.

Authors:  Deane Smith; Eugene A Grossi; Leora B Balsam; Patricia Ursomanno; Annette Rabinovich; Aubrey C Galloway; Abe DeAnda
Journal:  Aorta (Stamford)       Date:  2013-09-01

2.  The team focus on improving blood transfusion.

Authors:  D McMillan; P Brady; C Foot; R Levy; A Thomson
Journal:  J Extra Corpor Technol       Date:  2011-03

3.  [Bedside thrombelastography. Cost reduction in cardiac surgery].

Authors:  G J Spalding; M Hartrumpf; T Sierig; N Oesberg; C G Kirschke; J M Albes
Journal:  Anaesthesist       Date:  2007-08       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.